Navigation Links
Echo Therapeutics Reports Third Quarter 2007 Results
Date:11/20/2007

t to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to risks and uncertainties relating to our ability to develop, market and sell pharmaceutical or diagnostic products based on our AzoneTS and CTGM technologies, including AzoneTS-based Durhalieve for corticosteroid responsive dermatoses and the use of our SonoPrep ultrasound-mediated skin permeation technology platform with our CTGM system for the diabetes home use and hospital intensive and critical care markets; the success of our AzoneTS and CTGM business, research, development, and regulatory approval, marketing and distribution plans and strategies; and, our ability to raise sufficient capital in the future to fund our research and development programs, commercialize our product candidates and achieve profitability. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-KSB for the year ended December 31, 2006, our most recent quarterly reports on Form 10-QSB, and our current reports on Form 8-K. Echo Therapeutics, Inc. does not undertake to update these forward- looking statements.

Investor Relations Contacts:

Patrick T. Mooney, M.D., CEO

508-530-0329

pmooney@echotx.com

10 Forge Parkway

Franklin, MA 02038, USA

Tel: 1+ 877-476-6878

Fax: 1+ 508-553-8760

http://www.echotx.com

All rights reserved worldwide.

Echo Therapeutics, Inc.

(Formerly Sontra Medical Corporation)

Consolidated Balance Sheets

As of,

September 30, December 31,


'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Eckert & Ziegler Vitalea ... (AMS) services to the pharmaceutical and biotech industry, has ... company in the position of Director of Science & ... and valuable experience in drug metabolism and bioanalysis to ...
(Date:1/22/2015)... 2015 Cambridge Semantics, the leading provider of ... that 2014 was a record-breaking year across the board for ... Anzo Smart Data Platform and our Smart Data solutions, our ... diverse data which led to record growth for the company ...
(Date:1/22/2015)... January 22, 2015 zFlo Motion , ... to announce an exciting product from a new partner. ... solutions over the past 15 years, with offerings in the ... their 3D IMU system (inertial measurement unit), iSen, is opening ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... GENEVA, Sept. 11 Friendly LRL Holdings LLC ("FLH") ... to acquire all of the outstanding shares of common stock ... immediately. FLH,s offer was scheduled to expire at 11:59 ... All shares previously tendered pursuant to the tender offer ...
... ... a series of experiments to demonstrate the power of nanotechnology based regenerative medicines. ... (PRWEB) September 11, ... announced plans to attempt to rejuvenate living animals with advanced nanotechnologies developed by his ...
... HORSHAM, Pa., Sept. 10 Centocor Ortho Biotech Products, ... the U.S. Food and Drug Administration (FDA) regarding its Supplemental New ... in combination with docetaxel for the treatment of women ... , Centocor Ortho Biotech is evaluating the FDA,s letter ...
Cached Biology Technology:Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 2Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 3Matthew Sarad to Reverse Aging and Cure Cancer 2Matthew Sarad to Reverse Aging and Cure Cancer 3Matthew Sarad to Reverse Aging and Cure Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 2Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 3Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 5
(Date:1/22/2015)... 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics ... its new website design. "When we launched FindBiometrics ... Peter O,Neill , founder and CEO of FindBiometrics. "Now ... involvement from the key players on a very broad scale.  ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... link between schizophrenia and autism is enabling researchers to ... illnesses. Dr Steve Clapcote from the University of Leeds,s ... by mice with a genetic mutation linked to schizophrenia ... behavioural abnormalities. "We don,t fully understand how the ...
... studies published in the latest issue of Cell Transplantation ... of heart diseases. The first study, carried out by a ... marrow mononuclear cells (BMMCs) directly into the heart benefited patients ... researchers in the Peoples, Republic of China found that apelin, ...
... been elected to Fellowship in the American Academy ... elected annually through a highly selective, peer-review process, ... original contributions that have advanced microbiology. There are ... microbiology, including basic and applied research, teaching, public ...
Cached Biology News:Research builds on genetic link to autism and schizophrenia 2Bone marrow cell transplants to benefit those with heart disease 2Bone marrow cell transplants to benefit those with heart disease 3Bone marrow cell transplants to benefit those with heart disease 478 scientists elected to the American Academy of Microbiology 278 scientists elected to the American Academy of Microbiology 378 scientists elected to the American Academy of Microbiology 4
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
Anti Autotaxin /ENPP2 , - (Rabbit)...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
Biology Products: